A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors
ConditionAdvanced Malignancy
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSuzhou Suncadia Biopharmaceuticals Co., Ltd.
About this trial
The main objective of this study is to evaluate the effectiveness and safety of SHR-7782 for participants with advanced malignant cancer.
Eligibility criteria
Qualifiers
Participate in the study voluntarily, sign the informed consent form.
Subjects were able to provide primary or metastatic cancer samples.
At least one measurable lesion (RECIST version 1.1).
ECOG 0~1.
Disqualifiers
With untreated brain metastasis or active central nervous system tumor metastases.
Imaging shows that the tumor invades large blood vessels or has unclear boundaries with blood vessels.
Patients with other malignant tumors in the past or at the same time.
Patients with clinical symptoms, uncontrolled, or moderate or above pleural effusion, pericardial effusion, or peritoneal effusion.
Trial design
Treatments tested in this trial
- SHR-7782 Injection
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov